These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 32818927)
101. Solution structures of the YAP65 WW domain and the variant L30 K in complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the application of peptide libraries reveal a minimal binding epitope. Pires JR; Taha-Nejad F; Toepert F; Ast T; Hoffmüller U; Schneider-Mergener J; Kühne R; Macias MJ; Oschkinat H J Mol Biol; 2001 Dec; 314(5):1147-56. PubMed ID: 11743730 [TBL] [Abstract][Full Text] [Related]
102. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Macias MJ; Hyvönen M; Baraldi E; Schultz J; Sudol M; Saraste M; Oschkinat H Nature; 1996 Aug; 382(6592):646-9. PubMed ID: 8757138 [TBL] [Abstract][Full Text] [Related]
103. Non-destructive inhibition of metallofullerenol Gd@C(82)(OH)(22) on WW domain: implication on signal transduction pathway. Kang SG; Huynh T; Zhou R Sci Rep; 2012; 2():957. PubMed ID: 23233876 [TBL] [Abstract][Full Text] [Related]
104. FBP WW domains and the Abl SH3 domain bind to a specific class of proline-rich ligands. Bedford MT; Chan DC; Leder P EMBO J; 1997 May; 16(9):2376-83. PubMed ID: 9171351 [TBL] [Abstract][Full Text] [Related]
105. WW domain-containing proteins: retrospectives and the future. Salah Z; Alian A; Aqeilan RI Front Biosci (Landmark Ed); 2012 Jan; 17(1):331-48. PubMed ID: 22201747 [TBL] [Abstract][Full Text] [Related]
106. Recognition of proline-rich motifs by protein-protein-interaction domains. Ball LJ; Kühne R; Schneider-Mergener J; Oschkinat H Angew Chem Int Ed Engl; 2005 May; 44(19):2852-69. PubMed ID: 15880548 [TBL] [Abstract][Full Text] [Related]
107. Proline-rich sequence recognition domains (PRD): ligands, function and inhibition. Freund C; Schmalz HG; Sticht J; Kühne R Handb Exp Pharmacol; 2008; (186):407-29. PubMed ID: 18491062 [TBL] [Abstract][Full Text] [Related]
108. Structural insights into the functional versatility of WW domain-containing oxidoreductase tumor suppressor. Farooq A Exp Biol Med (Maywood); 2015 Mar; 240(3):361-74. PubMed ID: 25662954 [TBL] [Abstract][Full Text] [Related]
109. WW or WoW: the WW domains in a union of bliss. Sudol M; Recinos CC; Abraczinskas J; Humbert J; Farooq A IUBMB Life; 2005 Dec; 57(12):773-8. PubMed ID: 16393779 [TBL] [Abstract][Full Text] [Related]
110. Potential toxicity mechanism of MoS Meng Y; Liu R; Zhu M; Zhai H; Ren C Colloids Surf B Biointerfaces; 2020 Dec; 196():111317. PubMed ID: 32818927 [TBL] [Abstract][Full Text] [Related]
111. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. Macias MJ; Wiesner S; Sudol M FEBS Lett; 2002 Feb; 513(1):30-7. PubMed ID: 11911877 [TBL] [Abstract][Full Text] [Related]
112. Characterization of a novel protein-binding module--the WW domain. Sudol M; Chen HI; Bougeret C; Einbond A; Bork P FEBS Lett; 1995 Aug; 369(1):67-71. PubMed ID: 7641887 [TBL] [Abstract][Full Text] [Related]
113. Towards prediction of cognate complexes between the WW domain and proline-rich ligands. Einbond A; Sudol M FEBS Lett; 1996 Apr; 384(1):1-8. PubMed ID: 8797792 [TBL] [Abstract][Full Text] [Related]
114. The WW domain: linking cell signalling to the membrane cytoskeleton. Ilsley JL; Sudol M; Winder SJ Cell Signal; 2002 Mar; 14(3):183-9. PubMed ID: 11812645 [TBL] [Abstract][Full Text] [Related]